[1] |
XU Minyi, LIU Yaqi, LIU Yuxiu, XIONG Yin, GONG Haowen, ZHANG Manting, YU Xihui, ZHAO Yang.
BSD method for three treatments randomly allocated with equal proportion in clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 283-289.
|
[2] |
MIAO Yadong, LI Xi, WANG Yan, GAO Po, ZHOU Min, YU Hao.
General considerations for clinical data management of antineoplastic drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1055-1060.
|
[3] |
CHEN Jianfang, LOU Donghua.
Design of case report form for oncology clinical trials based on CDASH
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767.
|
[4] |
ZHANG Miao, LIU Qian, YAO Xueting, LIU Dongyang.
Exploration of early food effect study of innovative drugs based on physiologically-based pharmacokinetic absorption model
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1426-1429.
|
[5] |
ZHONG Zihang, CHEN Feng, YUAN Ying, CHENG Jiancheng, YU Xuanxuan, YANG Min, TAN Mingmin, ZHAO Yang, BAI Jianling, YU Hao.
A novel model-assisted design in phase I clinical trials: Bayesian optimal interval design
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 640-648.
|
[6] |
LUO Yi, JIANG Zhiwei.
Statistical consideration in the design of COVID-19 clinical trials in emergency
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 121-125.
|
[7] |
ZHOU Bei, YU Hao.
Classification and application of logic check in clinical trail
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 670-674.
|
[8] |
WANG Ao, CAI Jingjing, BAI Jianling, LIU Yue, YU Xuanxuan, CHEN Feng, ZHAO Yang, YU Hao.
Sample size estimation for average bioequivalence for highly variable drugs using two replicated crossover designs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 164-170.
|
[9] |
WANG Yafei, CHEN Feng, BAI Jianling, HUANG Lihong, YU Hao.
Statistical performance comparison of different simultaneous global development designs for targeted drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1127-1132.
|
[10] |
ZHAO De-heng, XIAO Hui-lai.
FDA's recommentdations on pharmacogenomics studies in early-phase clinical studies
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 208-212.
|
[11] |
LIANG Wei-xiong.
Frequent questions and attentions of applying add-on design to clinical study of Chinese medicine
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 96-100.
|
[12] |
QIAN Wei, XIAO Da-wei.
Phase Ⅰ clinical trial design and the problems need to focus
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(6): 654-660.
|
[13] |
CHEN Lin, LIU Yu-xiu, MIAO Hua-zhang.
Statistical performance comparison of different design methods of targeted clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 399-403.
|
[14] |
YU Li-li, BU Xiao-dong, GU Xin, DU Qian, XIA Jie-lai.
Explore on the effects of General Friedman's Urn Model on power in clinical trial through simulation experiments
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 286-289.
|
[15] |
GUO Yang, JIANG Zhi-wei, XIA Jie-lai, WANG Yu-kun.
Statistical considerations of group sequential design in oncology clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 175-180.
|